Wockhardt: Business Overview & Financial Analysis
Wockhardt Limited is a research-driven, global pharmaceutical and biotechnology enterprise headquartered in Mumbai, Maharashtra. Promoted by Habil Khorakiwala, the company operates across active pharmaceutical ingredients (APIs), generic and branded formulations, biopharmaceuticals, and novel anti-infective discovery. Utilizing state-of-the-art manufacturing plants in India and the United Kingdom, along with dedicated R&D facilities in India and Switzerland, Wockhardt serves healthcare systems across the UK, India, the US, Europe, and emerging international markets.
Geographic Revenue Mix of Wockhardt (Q4 FY26)
Wockhardt maintains an export-dominated revenue footprint, with international business generating over four-fifths of overall turnover.
- United Kingdom (UK) Business – 41.0%
- India Business – 17.0%
- Emerging Markets & Rest of World (RoW) – 18.0%
- United States (US) Business – 13.0%
- Europe (ex-UK) Business – 11.0%
The UK division serves as the primary revenue anchor, backed by generic medicine and fill-finish contracts with the National Health Service (NHS). The domestic India business and emerging markets provide secondary commercial revenue across chronic, diabetes care, and acute therapeutic segments.
Novel Anti-Infective (NCE) R&D Pipeline of Wockhardt (FY26)
Wockhardt directs significant research and development outlays toward discovering novel anti-infective molecules targeted at multi-drug resistant superbugs.
- WCK 5222 (Zidebactam / Cefepime) – Global Phase-III clinical trials underway; completion targeted in FY27
- WCK 4282 (Cefepime / Tazobactam) – Phase-III clinical trials completed; fast-track designation granted by USFDA
- WCK 6777 (Emsiporflo) – Phase-I clinical trials completed in US for once-a-day outpatient therapy
- Total QIDP Statuses Granted – 6 novel molecules granted Qualified Infectious Disease Product status by USFDA
- Total Granted Patents Base – 3,250+ patents granted globally
The company's primary drug discovery engine centers on WCK 5222, a novel broad-spectrum antibiotic undergoing global Phase-III clinical trials. USFDA QIDP designations provide priority review status and five years of market exclusivity upon regulatory approvals.
Manufacturing Infrastructure & USFDA Status of Wockhardt (FY26)
Wockhardt operates an integrated network of formulation, biopharmaceutical, and API manufacturing complexes across India and Europe.
- Total Operational Manufacturing Facilities – 12 manufacturing units globally (10 in India, 1 in UK, 1 in Ireland)
- Key Indian Plant Locations – Shendra (Aurangabad), Chikalthana (Aurangabad), Waluj (Aurangabad), Ankleshwar (Gujarat), and Daman
- UK Manufacturing Hub – Wrexham facility (Sterile injectables and NHS vaccine filling contracts)
- USFDA Regulatory Status – Active Establishment Inspection Report (EIR) received for Shendra facility
The Shendra manufacturing complex serves as the flagship sterile injectable and biopharmaceuticals facility, holding active EIR status from the USFDA. The Wrexham plant in the UK handles sterile filling, packaging, and institutional supply for healthcare systems.
UK Operations & Institutional Business of Wockhardt (Q4 FY26)
Wockhardt is a major supplier of generic formulations and sterile injectables to the UK National Health Service (NHS).
- UK Division Revenue (Q4 FY26) – Rs 342.00 crore (+16.5% YoY)
- NHS Supply Contribution Share – Supplies 1 out of every 10 generic medicine doses used by the NHS
- Insulin & Sterile Market Share – >30% market share in human insulin formulations in the UK
- Contract Manufacturing (CDMO) – Long-term supply contracts for fill-finish sterile injectables
The UK business achieved a 16.5% year-on-year revenue expansion in Q4 FY26, driven by higher demand for sterile injectables. Deep institutional supply relationships with the UK NHS provide steady volume distribution across retail and hospital networks.
Domestic India Business & Branded Portfolio of Wockhardt (Q4 FY26)
Wockhardt maintains a domestic formulation presence in India focused on prescription brand sales and diabetes care.
- Domestic India Revenue (Q4 FY26) – Rs 142.00 crore (+7.5% YoY)
- Core Therapeutic Segments – Diabetes Care, Pain Management, Cardiology, Anti-Infectives, and Dermatology
- Flagship Brands Portfolio – Wosulin (Human Insulin), Decdan, Methycobal, Zedex, and Bro-Zedex
- Active Field Force Strength – 1,800+ medical representatives across India
The domestic business is anchored by 'Wosulin', an in-house developed recombinant human insulin brand. Medical representative coverage supports prescription generation across hospitals, nursing homes, and retail chemist networks across Tier-1 to Tier-3 Indian cities.
Latest Quarterly Financial Performance of Wockhardt (Q4 FY26)
Wockhardt recorded top-line revenue expansion and operating profit growth during the fourth quarter of FY26.
- Consolidated Revenue from Operations – Rs 838.00 crore (+14.2% YoY)
- Operating EBITDA – Rs 118.00 crore (+38.8% YoY)
- Operating EBITDA Margin – 14.1% (+250 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 22.40 crore (vs Net Loss of Rs 74.00 crore in Q4 FY25)
Fourth-quarter operating revenue rose 14.2% year-on-year to Rs 838.00 crore, supported by volume recovery in the UK and emerging markets. Consolidated Net Profit After Tax reached Rs 22.40 crore, marking a turnaround to profitability due to operational leverage and lower interest expenses.
Consolidated Annual Financial Performance of Wockhardt (FY26)
Wockhardt delivered revenue expansion and a turnaround in operating profitability for full financial year FY26.
- Full Year Consolidated Revenue from Operations – Rs 3,250.40 crore (+13.8% YoY)
- Full Year Operating EBITDA – Rs 435.20 crore (+42.5% YoY)
- Full Year Operating EBITDA Margin – 13.4% (+270 bps YoY)
- Full Year Consolidated Net Profit After Tax (PAT) – Rs 62.80 crore (vs Net Loss of Rs 322.00 crore in FY25)
Full-year operating revenue reached Rs 3,250.40 crore in FY26, as consolidated Net Profit After Tax turned positive at Rs 62.80 crore. Financial performance benefited from higher sterile injectable dispatches in the UK and reduced interest burdens following debt prepayments.
Financial Position & Balance Sheet Metrics of Wockhardt (Q4 FY26)
Wockhardt executes debt reduction programs using cash accruals and equity capital raised through qualified institutional placements.
- Gross Financial Debt – Rs 780.00 crore (reduced from Rs 1,650.00 crore in FY24)
- Net Debt to Operating EBITDA Ratio – 1.65x
- QIP Capital Raised (FY25/FY26) – Rs 570.00 crore (utilised for debt prepayments and NCE R&D trials)
- Return on Capital Employed (ROCE) – 8.8%
Gross debt compressed to Rs 780.00 crore as of March 31, 2026, down from peak levels exceeding Rs 1,650.00 crore. Equity proceeds from QIP issuances facilitated long-term debt prepayments, lowering annual interest burdens.
Management Commentary & Strategic Outlook of Wockhardt (Q4 FY26 / FY27)
Management guidance highlights strategic priorities centered on completing global Phase-III clinical trials for WCK 5222, debt reduction, and UK market expansion.
- Management targets sustaining double-digit top-line revenue growth across the UK and emerging markets during FY27.
- Operating EBITDA margins are guided to improve toward the 15.0%–18.0% corridor as biopharmaceutical capacity utilization scales.
- H2 FY27 will complete global Phase-III clinical trial enrollment for novel anti-infective WCK 5222.
- Debt prepayments will continue with an objective to achieve net-zero debt status on a standalone basis over the next 18 to 24 months.
- Commercial licensing and out-licensing partnerships for WCK 5222 in North America, Europe, and Asia will be finalized post-Phase-III readouts.
Management expects global volume demand for sterile injectables and diabetes care products to remain strong. Strategic focus centers on advancing the novel antibiotic pipeline through global Phase-III trials, maintaining USFDA compliance across manufacturing units, and completing balance sheet deleveraging.
Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.
Sources & References
- Wockhardt Limited Q4 & Full Year FY26 Consolidated Financial Results Disclosures (May 2026)
- Wockhardt Limited Q4 FY26 Investor Presentation & Fact Sheet (May 2026)
- Wockhardt Limited Q4 FY26 Earnings Conference Call Transcript (May 2026)
- BSE India & NSE Official Corporate Announcements for Wockhardt Limited
- Ticker Finology Wockhardt Page
Disclaimer
The information presented above on Wockhardt Limited has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Wockhardt Limited page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.